Victorian brain cancer researchers have achieved a global-first, using an innovative process to learn how a new drug ...

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, ...

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 ...

Rosa Tellez-Moore finds hope and healing through groundbreaking research at UC San Diego Health Rosa Tellez-Moore is grateful ...

In this episode of the Applied Clinical Trials Brief, we recap our three most-viewed stories of the week—covering the Supreme Court’s decision to uphold NIH funding cuts tied to DEI, Phase II data ...

Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs or the Company, Stock Code: 9887.HK) today announced the first patient has ...

Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...

EmVenio Clinical Research expands global trial access with brand consolidation and launches Patient Navigator™ to improve access for trial participants.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod ...

U.S. and China regulators have now cleared Sineugene Therapeutics' ALS gene therapy SNUG01 for clinical trials.